Lupin Limited, a major international pharmaceutical company, announced that its wholly-owned subsidiary, Nanomi B.V., has completed an agreement to acquire VISUfarma B.V. VISUfarma, a company backed by GHO Capital Partners LLP, focuses on products related to eye health and has a strong commercial presence in Europe. This acquisition aligns with Lupin’s plan to grow its specialty pharmaceutical business and increase its presence in Europe. By integrating VISUfarma’s well-established operations, Lupin aims to take advantage of the growing ophthalmology market, which is expanding due to an aging population, increased cases of diabetes-related eye issues, and a greater emphasis on preventive eye care.
Health Technology Insights: Actio Biosciences Begins Trial for KCNT1 Epilepsy Treatment
VISUfarma operates in key European countries such as Italy, the UK, Spain, Germany, and France, offering Lupin opportunities to expand its market reach and diversify its business. The company offers more than 60 branded ophthalmology products, covering a variety of conditions, including dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized nutraceuticals. Lupin expects this acquisition to boost its growth in Europe and strengthen its position in the specialty pharmaceutical sector globally.
Health Technology Insights: Java Medical, TruBridge Expand EHR and Financial Tech Deal
Vinita Gupta, CEO of Lupin, expressed excitement about the deal, stating, “We are thrilled to welcome VISUfarma into the Lupin family. This acquisition supports our mission to provide innovative medicines to patients and enhances our position in Europe while advancing our ophthalmology business.” She added that integrating VISUfarma will allow Lupin to offer a comprehensive eye care portfolio to cater to various patient needs.
The acquisition will be funded using Lupin’s current cash reserves. It is expected to benefit Lupin’s growth and profitability. The transaction is anticipated to close by the end of 2025, subject to regulatory approvals and other typical closing conditions.
Andrea Ponti, Managing Partner at GHO Capital, and Mike Turner, Partner at GHO Capital, reflected on their successful partnership with VISUfarma, noting its transformation from a mainly Italian company into a strong pan-European business. They expressed confidence that working with Lupin will help VISUfarma continue to grow and build a global ophthalmology brand. Paolo Cioccetti, CEO Italy at VISUfarma, welcomed the acquisition, calling it an exciting new chapter that will allow VISUfarma to expand its impact on eye care worldwide. He thanked GHO Capital for their support, acknowledging their role in the company’s growth into a European leader in ophthalmic pharmaceuticals.
Financial and legal advisory roles in the transaction were handled by Centerview Partners UK LLP and Herbert Smith Freehills Kramer LLP for Lupin. GHO Capital was advised by Stifel on financial matters and by Slaughter and May, Giliberti Triscornia e Associati, Norton Rose Fulbright, and Deloitte for legal and tax guidance.
Health Technology Insights: FNIH Awards David Liu First Montrone-Seigel Prize
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
